drugset / Trial / NCT02473952
A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The primary objective is to evaluate whether IGIV-C improves MG symptoms as compared to placebo in subjects with MG.
Timeline
- Start
- 2015-08
- Primary completion
- 2018-01
- Completion
- 2018-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Immune Globulin Intravenous (Human) | Protein / enzyme biologic | 1 g/kg | Intravenous |